Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 33%
Hold 20%
Sell 7%
Strong Sell 0%

Bulls say

Tempus AI is a promising technology company with a positive outlook due to their recent acquisition of PSNL, expected growth in commercialization and a target price upgrade to $76, and successful developments, such as FDA approval for a tumor testing product. There is also potential for further growth through their personalized neoantigen therapy and partnerships in manufacturing personalized cancer vaccines. However, risks include achieving projected earnings, competition, and potential financial losses and volatility.

Bears say

Tempus AI is currently trading at a high multiple and has a high price target, but with increasing competition in the healthcare technology industry and the potential limitations around Intismeran's CDx designation, there are concerns about the company's future revenue growth. Additionally, while Tempus has multiple potential revenue streams, including partnerships with Merck and Moderna, these opportunities are still in the early stages and may not generate significant revenue in the near term. Finally, while yesterday's positive Phase 3 readout for personalized neoantigen therapy is a positive development, it may take some time for it to translate into meaningful financial impact for the company.

TEM has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 33% recommend Buy, 20% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 15 analysts, TEM has a Buy consensus rating as of Sep 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.